Novartis India headcount shows promise as investors express enthusiasm over the Rs 1,400 cr deal.
Sun Pharma quarterly profit shows a decline due to one-time charges affecting earnings.
FDA approval Teva marks a significant advancement in schizophrenia treatment with Weltruza.
Capricor DMD therapy faces challenges as the company launches a legal fight ahead of the FDA review.
